A new University of Cincinnati Cancer Center study has identified a particular strand of microRNA as a promising new target for overcoming breast cancer treatment resistance and improving outcomes.
Mirxes, a leading Singapore-based cancer detection firm, has secured $40 million in financing from CBC Group's R-Bridge Fund to enhance its innovative miRNA technology platform. The investment aims to ...